[go: up one dir, main page]

DK3319980T3 - Formuleringer til forbedring af virkningen af hydrofobe lægemidler - Google Patents

Formuleringer til forbedring af virkningen af hydrofobe lægemidler Download PDF

Info

Publication number
DK3319980T3
DK3319980T3 DK16824940.7T DK16824940T DK3319980T3 DK 3319980 T3 DK3319980 T3 DK 3319980T3 DK 16824940 T DK16824940 T DK 16824940T DK 3319980 T3 DK3319980 T3 DK 3319980T3
Authority
DK
Denmark
Prior art keywords
formulations
improve
effect
hydrophobic medicines
medicines
Prior art date
Application number
DK16824940.7T
Other languages
English (en)
Inventor
William L Elliott
Reynold Homan
Original Assignee
Peptinovo Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptinovo Biopharma Inc filed Critical Peptinovo Biopharma Inc
Application granted granted Critical
Publication of DK3319980T3 publication Critical patent/DK3319980T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
    • A61K49/0082—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion micelle, e.g. phospholipidic micelle and polymeric micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Botany (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK16824940.7T 2015-07-10 2016-07-08 Formuleringer til forbedring af virkningen af hydrofobe lægemidler DK3319980T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562190909P 2015-07-10 2015-07-10
PCT/US2016/041544 WO2017011312A1 (en) 2015-07-10 2016-07-08 Formulations for improving the efficacy of hydrophobic drugs

Publications (1)

Publication Number Publication Date
DK3319980T3 true DK3319980T3 (da) 2021-11-22

Family

ID=57758158

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16824940.7T DK3319980T3 (da) 2015-07-10 2016-07-08 Formuleringer til forbedring af virkningen af hydrofobe lægemidler

Country Status (12)

Country Link
US (1) US10532105B2 (da)
EP (1) EP3319980B8 (da)
JP (4) JP2018528257A (da)
KR (1) KR20180027532A (da)
CN (1) CN108350036B (da)
AU (1) AU2016291597B2 (da)
CA (1) CA2991655A1 (da)
DK (1) DK3319980T3 (da)
EA (1) EA201890271A1 (da)
IL (1) IL256486B2 (da)
MX (1) MX384254B (da)
WO (1) WO2017011312A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180027532A (ko) * 2015-07-10 2018-03-14 펩티노보 바이오파마, 엘엘씨 소수성 약물의 효능 개선용 제형
US11174288B2 (en) 2016-12-06 2021-11-16 Northeastern University Heparin-binding cationic peptide self-assembling peptide amphiphiles useful against drug-resistant bacteria
WO2021030359A1 (en) * 2019-08-13 2021-02-18 Peptinovo Biopharma, Llc Palm for the treatment of chemotherapy-induced peripheral neuropathy incidental to the treatment of cancer
CA3187253A1 (en) * 2020-08-11 2022-02-17 Reynold Homan Peptides and formulations for cancer treatment

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6287590B1 (en) 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US20040234588A1 (en) 2000-09-21 2004-11-25 University Of Georgia Research Foundation, Inc. Artificial lipoprotein carrier system for bioactive materials
AUPR798901A0 (en) 2001-09-28 2001-10-25 Medvet Science Pty. Ltd. Spheroidal hdl particles with a defined phospholipid composition
CA2486127C (en) 2002-05-17 2014-03-11 Esperion Therapeutics, Inc. Method of treating dyslipidemic disorders
CA2791165C (en) 2002-12-03 2015-02-24 Blanchette Rockefeller Neurosciences Institute A conjugate comprising cholesterol linked to tetracycline
WO2005070400A1 (en) 2004-01-15 2005-08-04 Mount Sinai School Of Medicine Methods and compositions for imaging
GB0525214D0 (en) 2005-12-12 2006-01-18 Bioinvent Int Ab Biological materials and uses thereof
WO2008124026A1 (en) * 2007-04-05 2008-10-16 Wyeth Wortmannin-rapamycin conjugate and uses thereof
US20090110739A1 (en) 2007-05-15 2009-04-30 University Of North Texas Health Science Center At Forth Worth Targeted cancer chemotherapy using synthetic nanoparticles
CN102177176B (zh) 2007-10-23 2014-05-07 克里夫兰临床基金会 氧化剂耐受性载脂蛋白a-1及模拟肽
WO2009059450A1 (en) * 2007-11-05 2009-05-14 Shanghai Jiaotong University Peptide ligand directed drug delivery
EP2229411B1 (en) 2007-12-12 2019-02-27 University Health Network High-density lipoprotein-like peptide-phospholipid scaffold ("hpps") nanoparticles
PL2279254T3 (pl) * 2008-04-15 2017-11-30 Protiva Biotherapeutics Inc. Nowe preparaty lipidowe do dostarczania kwasów nukleinowych
CN102123722A (zh) * 2008-06-18 2011-07-13 加利福尼亚大学董事会 改进的胆固醇流出的肽介质
AU2009293140A1 (en) * 2008-09-17 2010-03-25 Endocyte, Inc. Folate receptor binding conjugates of antifolates
EP2393472B1 (en) 2008-12-05 2019-06-05 NanoMed Holdings Pty Ltd Amphiphile prodrugs
EP2658993B1 (en) * 2010-12-31 2014-10-01 Alphacore Pharma LLC Detection of lcat activity
JP2014132832A (ja) * 2011-05-10 2014-07-24 Sekisui Chem Co Ltd 医薬、機能性食品、目的蛋白質の安定化方法、融合蛋白質、核酸、並びに、組換え体
AU2013274101B2 (en) * 2012-06-15 2017-09-07 The Brigham And Women's Hospital, Inc. Compositions for treating cancer and methods for making the same
CN103393597B (zh) * 2013-07-02 2015-06-17 北京大学 疏水性肽修饰的注射用长循环脂质体给药系统
CN104558117B (zh) * 2013-10-25 2018-01-16 复旦大学 一种乙酰胆碱受体介导靶向的d构型多肽及其应用
US10220046B2 (en) 2014-07-14 2019-03-05 The Regents Of The University Of Michigan Compositions and methods for disease treatment using nanoparticle delivered compounds
WO2016019333A1 (en) 2014-07-31 2016-02-04 Kinemed, Inc. The effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties
KR20180027532A (ko) * 2015-07-10 2018-03-14 펩티노보 바이오파마, 엘엘씨 소수성 약물의 효능 개선용 제형

Also Published As

Publication number Publication date
EP3319980A1 (en) 2018-05-16
EP3319980B8 (en) 2021-11-03
KR20180027532A (ko) 2018-03-14
IL256486B2 (en) 2023-07-01
IL256486B1 (en) 2023-03-01
JP2023153906A (ja) 2023-10-18
JP2025172117A (ja) 2025-11-20
AU2016291597B2 (en) 2021-01-14
EA201890271A1 (ru) 2019-01-31
CN108350036B (zh) 2022-04-08
HK1256864A1 (zh) 2019-10-04
JP2018528257A (ja) 2018-09-27
JP2021191767A (ja) 2021-12-16
AU2016291597A1 (en) 2018-02-01
CN108350036A (zh) 2018-07-31
EP3319980A4 (en) 2019-02-13
US10532105B2 (en) 2020-01-14
CA2991655A1 (en) 2017-01-19
NZ738934A (en) 2025-02-28
IL256486A (en) 2018-02-28
MX384254B (es) 2025-03-14
US20190076544A1 (en) 2019-03-14
EP3319980B1 (en) 2021-09-29
MX2018000140A (es) 2018-06-22
WO2017011312A1 (en) 2017-01-19
JP7378446B2 (ja) 2023-11-13

Similar Documents

Publication Publication Date Title
EP3509581A4 (en) FORMULATIONS OF (R
HUE047477T2 (hu) Palbociclib szilárd dózisformái
DK3383363T3 (da) Topiske farmaceutiske formuleringer til behandling af inflammatorisk-relaterede tilstande
EP3513809A4 (en) MEDICAL COMPOSITION
EP3337502A4 (en) STABLE ANTI-IFNAR1 FORMULATION
DK3529248T3 (da) Farmaceutiske sammensætninger
PL4070788T3 (pl) Formulacje farmaceutyczne
DK3261721T3 (da) Anvendelse af pridopidin til forbedring af hukommelse
DK3116491T3 (da) Farmaceutiske sammensætninger af terapeutisk aktive forbindelser
DK3237045T3 (da) Indretning til indgivelse af lægemidler
EP3406336A4 (en) NANO FOIL OF CORE CASE STRUCTURE TYPE
CL2016001313A1 (es) Formulaciones listas de fertilizante líquido de bifentrina.
EP3364945C0 (en) SOLID FORMULATION
DK3474822T3 (da) Formuleringer af brincidofovir
DK3137053T3 (da) Formuleringer af biologiske lægemidler til intravesikal instillation
MA44987A (fr) Formulations de médicaments améliorées
DK3297619T3 (da) Terapeutiske anvendelser af L-4-chlorkynurenin
IL254502A0 (en) Solid forms of menaquinols
DK3307239T3 (da) Formuleringer til indgivelse af RSV- og norovirusantigener i tyndtarmen
DK3310331T3 (da) Injicerbare farmaceutiske formuleringer af lefamulin
DK3280447T3 (da) Farmaceutiske formuleringer
IL258630A (en) Formulation of l-ornithine phenylacetate
DK3173071T3 (da) Formularing af maropitant
DK3319980T3 (da) Formuleringer til forbedring af virkningen af hydrofobe lægemidler
IT201700091364A1 (it) Insieme strutturato per realizzare strutture satellitari